Future trends in the development of safer nonsteroidal anti-inflammatory drugs (Q40831716)

24 September 2017

1 reference

title

Future trends in the development of safer nonsteroidal anti-inflammatory drugs (English)

1 reference

24 September 2017

M M Wolfe

1

1 reference

PubMed ID

9855176

24 September 2017

language of work or name

English

0 references

publication date

1 November 1998

1 reference

American Journal of Medicine

24 September 2017

1 reference

24 September 2017

105

1 reference

24 September 2017

5A

1 reference

24 September 2017

44S-52S

1 reference

Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer. A randomized, controlled trial

24 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900281-2

Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900281-2

Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900281-2

A double-blind comparison of the gastroduodenal safety and efficacy of diclofenac and a fixed dose combination of diclofenac and misoprostol in the treatment of rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900281-2

A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900281-2

Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900281-2

Double-blind, placebo-controlled endoscopic comparison of the mucosal protective effects of misoprostol versus cimetidine on tolmetin-induced mucosal injury to the stomach and duodenum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900281-2

Misoprostol reduces gastroduodenal injury from one week of aspirin: an endoscopic study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900281-2

7 January 2021

Towards a better aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900281-2

Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900281-2

Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900281-2

Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900281-2

Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900281-2

Developmental expression of the cyclo-oxygenase-1 and cyclo-oxygenase-2 genes in the peri-implantation mouse uterus and their differential regulation by the blastocyst and ovarian steroids.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900281-2

Multiple female reproductive failures in cyclooxygenase 2-deficient mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900281-2

Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900281-2

A double-blind gastroscopic evaluation of the effects of etodolac and naproxen on the gastrointestinal mucosa of rheumatic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900281-2

A randomized double-blind comparison of placebo, etodolac, and naproxen on gastrointestinal injury and prostaglandin production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900281-2

Human whole blood assays for inhibition of prostaglandin G/H synthases-1 and -2 using A23187 and lipopolysaccharide stimulation of thromboxane B2 production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900281-2

Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900281-2

Effects of nabumetone on prostanoid biosynthesis in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900281-2

Safety of meloxicam: a global analysis of clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900281-2

Meloxicam: selective COX-2 inhibition in clinical practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900281-2

A 4-week, double-blind, parallel-group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg, piroxicam 20 mg and placebo by means of faecal blood loss, endoscopy and symptom evaluation in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900281-2

Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900281-2

NO-naproxen vs. naproxen: ulcerogenic, analgesic and anti-inflammatory effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900281-2

Inhibition of inducible nitric oxide synthase expression by novel nonsteroidal anti-inflammatory derivatives with gastrointestinal-sparing properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900281-2

A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900281-2

Inhibition of nitric oxide synthase delays healing of chronic gastric ulcers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900281-2

Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: Insight into the mechanism and reversal of NSAID-induced gastrointestinal injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900281-2

Nonsteroidal anti-inflammatory drug and phospholipid prodrugs: combination therapy with antisecretory agents in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900281-2

Effect of omeprazole on the bioavailability of unmodified and phospholipid-complexed aspirin in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900281-2

Stereoselective inhibition of inducible cyclooxygenase by chiral nonsteroidal antiinflammatory drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900281-2

Effect of the enantiomers of flurbiprofen, ibuprofen, and ketoprofen on intestinal permeability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900281-2

Pancreatic spasmolytic polypeptide (PSP): I. Preparation and initial chemical characterization of a new polypeptide from porcine pancreas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900281-2

Solution structure of a trefoil-motif-containing cell growth factor, porcine spasmolytic protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900281-2

The expression of the trefoil peptides pS2 and human spasmolytic polypeptide (hSP) in 'gastric metaplasia' of the proximal duodenum: implications for the nature of 'gastric metaplasia'.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900281-2

Epidermal growth factor (EGF/URO) induces expression of regulatory peptides in damaged human gastrointestinal tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900281-2

Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900281-2

Transgenic mice that overexpress the human trefoil peptide pS2 have an increased resistance to intestinal damage.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900281-2

Oral trefoil peptides protect against ethanol- and indomethacin-induced gastric injury in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900281-2

Prostaglandins and gastric ulcers: from seminal vesicle to misoprostol (Cytotec).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900281-2

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9343(98)00281-2

1 reference

24 September 2017

1 reference

PubMed ID

9855176